Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Memantine fails early AD trial

Forest Laboratories (FRX) said its Memantine plus acetylcholinesterase inhibitors failed to significantly improve

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE